Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
alnylam pharmaceuticals
boston
boston blog main
boston top stories
fda
hereditary transthyretin amyloidosis
4
×
life sciences
national blog main
national top stories
patisiran
akcea therapeutics
clinical trials
inotersen
new york blog main
new york top stories
rna interference
san diego blog main
san diego top stories
tafamidis
biotech
drugs
onpattro
pfizer
san francisco blog main
san francisco top stories
vyndaqel
alexion pharmaceuticals
andrew fire
barry greene
boehringer ingelheim
boston university
craig mello
dan ollendorf
deals
dicerna pharamceuticals
european medicines agency
harvard pilgrim health care
hepatitis b
hepatitis b virus
institute for clinical and economic review
What
alnylam
drug
fda
medicine
gene
pharmaceuticals
protein
rna
rnai
uses
afternoon
ago
alnylam’s
approve
approved
approves
awaits
biological
caught
causing
cells
crossed
decades
decision
dicerna
discovered
disease
ema
employ
europe
eye
fingers
follows
friday
gets
harmful
hepatitis
historic
history
hits
Language
unset
Current search:
" hereditary transthyretin amyloidosis "
×
@xconomy.com
4 years ago
Roche to Pay Dicerna Pharma $200M to Team Up on Hepatitis B Drug
@xconomy.com
5 years ago
RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug
@xconomy.com
5 years ago
Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug
@xconomy.com
5 years ago
Patients Have “Fingers Crossed” As Alnylam Awaits Historic FDA Decision